C. Lehn

Pathological Response and Survival in Triple-Negative Breast Cancer Following Neoadjuvant Carboplatin plus Docetaxel

C. Perou, A. Picornell, H. Gómez, 2018, Clinical Cancer Research.

Clinical Activity of Pembrolizumab in a Patient With Metastatic Triple-Negative Breast Cancer Without Tumor Programmed Death-Ligand 1 Expression: A Case Report and Correlative Biomarker Analysis.

A. Godwin, O. Tawfik, R. Jensen, 2017, JCO precision oncology.

Prognosis of triple negative breast cancer patients who attain pathological complete response with neoadjuvant carboplatin/docetaxel and do not receive adjuvant anthracycline chemotherapy.

A. Godwin, B. Kimler, R. Jensen, 2016 .